Noeul, an AI-based blood and cancer diagnostic platform company, announced on the 14th that it will participate in MEDICA 2023, the world's largest medical device exhibition held in D?sseldorf, Germany, from the 13th to the 16th (local time). MEDICA is the world's largest medical device exhibition held annually in D?sseldorf. This year, about 5,000 companies from around the world are participating to showcase new products and technologies.
A visitor at the Noeul booth set up at 'MEDICA 2023' held in D?sseldorf, Germany, is listening to an introduction about the cervical cytology test product. [Photo by Noeul]
With this participation, Noeul, attending MEDICA for the third consecutive time, plans to showcase its major MyLab product lineup, including malaria, blood analysis, and cervical cytology test products powered by the AI-based MyLab diagnostic platform.
On the first day of the exhibition (local time), Noeul discussed commercialization plans for MyLab with representatives from over 60 institutions and companies visiting its booth. Companies from Europe and Southeast Asian countries showed great interest in distributing blood analysis and cervical cytology test products. Additionally, companies from Africa as well as European countries such as Italy actively proposed domestic commercialization plans for malaria products to respond to increased demand due to climate change.
Kim Taehwan, head of Noeul's European branch, said, "Through participation in MEDICA 2023, we will accelerate the establishment of partnerships in the fields of malaria, blood analysis, and cervical cancer, and actively secure opportunities to expand into the global market."
The MyLab diagnostic platform is a next-generation staining and immunodiagnostic (NGSI) technology combined with AI in a compact all-in-one diagnostic platform, claiming to be a First-in-Class product in the market. It provides blood and tissue analysis results by combining highly scalable cartridges for each diagnostic field such as malaria, blood analysis, and cervical cytology tests. The test results from MyLab can be conveniently reviewed on the user's monitor regardless of location and time, and include features that allow users to change cell categories based on their judgment and transmit results, making it an optimized system for telemedicine environments.
© The Asia Business Daily(www.asiae.co.kr). All rights reserved.

